Financial Highlights – Oxford Nanopore Technologies (LSE: ONT) – FY25 Results

  • Revenue Growth: FY25 revenue rose 2% CC (22.2% reported) to £223.9m, slightly ahead of the top end of guidance.
  • Regional Momentum: All regions delivered over 20% CC growth — EMEAI +26.3%, APAC +23.2%, AMR +22.2% year-on-year.
  • End-Market Expansion: Strong performance across segments — Clinical +59.9%, BioPharma +30.4%, Applied Industrial +27.2%, Research +15.1%.
  • Product Performance: PromethION range surged 1%, MinION grew 2.4%, while other revenue (kits, services, devices) increased 12.0%.
  • Margin Improvement: Gross margin improved to 6% (+110bps); adjusted gross margin stood at 59.4% despite restructuring and inventory impacts.
  • EBITDA Progress: Adjusted EBITDA loss narrowed to £ (86.7) m from £(117.9) m, reflecting higher gross profits and disciplined cost control.
  • Strong Liquidity: Cash and liquid investments remained robust at £302.8m as of 31 December 2025.
  • FY26 Outlook: Revenue growth guided at 21–25% CC, gross margin around 62%, with operating cost growth limited to 0–5% and EBITDA breakeven targeted for FY27.

Oxford Nanopore Technologies (LSE: ONT)

Oxford Nanopore Technologies (LSE: ONT), is a UK-based biotechnology company focused on real-time, portable DNA and RNA sequencing technologies. Its proprietary nanopore platform supports scalable applications across research, clinical diagnostics, biopharma and industrial markets. The company has delivered strong double-digit revenue growth, driven by rising adoption of the PromethION platform and improving gross margins. Supported by a robust cash position of £302.8m, continued product innovation, regulatory progress and global expansion initiatives underpin its long-term growth framework.

Oxford Nanopore Technologies FY25 Growth Momentum: Can Margin Expansion and Strategic Focus Drive the Next Phase?

Oxford Nanopore Technologies (LSE: ONT) delivered strong revenue growth ahead of guidance, supported by broad-based demand across regions and end markets. Expansion in clinical, biopharma and applied industrial segments highlighted rising platform adoption, while continued product innovation across its sequencing portfolio strengthened commercial traction. Margin improvement reflected pricing optimisation and operational efficiencies, alongside disciplined cost management that narrowed losses year on year. The company remains well capitalised with a solid balance sheet, while ongoing focus on manufacturing scalability, regulated readiness and strategic partnerships positions it for sustainable medium-term growth.

Technical View: Oxford Nanopore Technologies Holds Near Key Level After Sharp Move – Will 100–90 Act as Base?

From a technical perspective, Oxford Nanopore Technologies (LSE: ONT) is currently trading around GBX 114.70, remaining below its 50-day Simple Moving Average near GBX 142.41, which now acts as an immediate technical barrier. The recent decline has shifted the short-term structure into a consolidation phase, with momentum cooling notably. The 14-day RSI at 28.18 signals oversold conditions, indicating stretched downside pressure. Immediate support is seen in the GBX 100–90 zone, while any recovery may encounter resistance within the GBX 135–148 range in the near term.

Bottom Line: Can ONT’s Fundamentals Cushion Near-Term Volatility?

Oxford Nanopore Technologies (LSE: ONT) continues to demonstrate robust revenue growth, margin improvement and disciplined cost management, reinforcing its medium-term strategic direction. Despite the recent share price decline, the company remains well capitalised with a solid cash position, supporting ongoing innovation and commercial expansion. Execution in higher-growth applied markets and progress toward EBITDA breakeven in FY27 remain central themes. Near-term price movements may reflect sentiment shifts, but operational delivery and margin progression are likely to guide the broader trajectory.